Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Brichard
Christopher J. Brichard, Pasadena, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110270246 | IRRIGATED ABLATION CATHETER WITH IMPROVED FLUID FLOW - An irrigated ablation catheter includes a tip electrode with a thin shell and a plug to provide a plenum chamber. The tip electrode has an inlet of a predetermined size and noncircular shape, and outlets in the form of fluid ports formed in the thin shell wall. The plurality of the fluid ports is predetermined, as is their diameter. The tip electrode thus considers a diffusion ratio of total fluid output area to fluid input area, and a fluid port ratio. The tip electrode also considers a fluid inlet aspect ratio where the fluid inlet has a noncircular (for example, oval or elliptical) radial cross-section. The plenum chamber has a narrow proximal portion opening to a wider distal portion so that fluid pressure decreases while fluid velocity increases with the desired effect of increased turbulence which decreases momentum for a more uniform distribution of fluid in the tip electrode. Extending distally from the plug is a baffle member shaped to diffuse fluid entering the tip electrode and to house an electromagnetic position sensor. | 11-03-2011 |
Dominique Brichard, San Jose, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100261961 | HERMETICALLY SEALED DISTAL SENSOR ENDOSCOPE - In one embodiment, an endoscopic camera for a robotic surgical system includes a stereo camera module mounted to a robotic arm of a patient side cart. The optical and electro-optic components of the camera module are hermetically sealed within a first housing. Signals from an electro-optic component travel through traces in a ceramic substrate forming one side of the hermetically sealed first housing. A second housing surrounds the first housing and optical fibers are dispersed between the housings to provide lighting in a body cavity. The camera module may be sterilized by an autoclave. | 10-14-2010 |
Gontran Brichard, Sart-Tilman BE
| Patent application number | Description | Published |
|---|---|---|
| 20100144836 | Methods for Detecting Epigenetic Modifications - A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, 11112, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases. The invention also relates to methods for identifying, diagnosing, staging or otherwise characterizing cancers, in particular gastrointestinal cancers such as colorectal cancers, gastric cancers and oesophageal cancers. The methods of the invention relate, inter alia, to isolating and analyzing the human DNA component from faecal samples and blood-based samples. | 06-10-2010 |
Marie-Hèléne Brichard, Gembloux BE
| Patent application number | Description | Published |
|---|---|---|
| 20110046349 | PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE - Exenatide, a polypeptide having the 39 amino acid sequence | 02-24-2011 |
Marie-Hèléne Brichard, Gembloux BE
| Patent application number | Description | Published |
|---|---|---|
| 20110046349 | PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE - Exenatide, a polypeptide having the 39 amino acid sequence | 02-24-2011 |
Vincent Brichard, Rixensart BE
| Patent application number | Description | Published |
|---|---|---|
| 20090186049 | METHOD OF TREATING MAGE POSITIVE CANCER - The present invention relates to methods for treating a range of cancers, for example MAGE positive cancers, including, but not limited to melanoma and non-small cell lung cancer (NSCLC). The present invention relates to methods for treating cancer in the adjuvant (eg. post-operative) setting and the active disease setting. | 07-23-2009 |
| 20100008980 | Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of Cancer - A combination therapy comprising an immunotherapy based on a tumour antigen or an immunological derivative thereof, and at least one other treatment for cancer such as chemotherapy, radiotherapy and/or surgery. | 01-14-2010 |
| 20100021424 | Method For Identifying Whether A Patient Will Be Responder or Not to Immunotherapy - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles and new diagnostic kits and methods. The invention further relates to treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from Mage expressing tumours. | 01-28-2010 |
| 20100029912 | Fusion Protein - Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells. | 02-04-2010 |
| 20110070268 | Method - Methods for characterisation of patients as responders or non-responders to therapy based on differential expression of one or more genes are provided. Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods of treatment are also provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours. | 03-24-2011 |